First Tracks Biotherapeutics (HAM:B43) OCF Yield %: -9.95 (As of Jul. 13, 2026)


HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €32.00
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics OCF Yield %?

First Tracks Biotherapeutics HAM:B43 +29.29% 20 OCF Yield % is -9.95 as of Jul. 13, 2026. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,410 Biotechnology companies, First Tracks Biotherapeutics ranks worse than 53.9% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, First Tracks Biotherapeutics's Trailing 12-Month Cash Flow from Operations is €-120.15 Mil, and Market Cap is €1,110.38 Mil. Therefore, First Tracks Biotherapeutics's OCF Yield % for today is -9.95%.

The historical rank and industry rank for First Tracks Biotherapeutics's OCF Yield % or its related term are showing as below:

HAM:B43' s OCF Yield % Range Over the Past 10 Years
Min: -9.95   Med: 0   Max: -9.95
Current: -9.95

During the past 2 years, the highest OCF Yield % of First Tracks Biotherapeutics was -9.95%. The lowest was -9.95%. And the median was %.

HAM:B43's OCF Yield % is ranked worse than
53.9% of 1410 companies
in the Biotechnology industry
Industry Median: -8.315 vs HAM:B43: -9.95

First Tracks Biotherapeutics's OCF Margin % for the quarter that ended in Dec. 2024 was %.

First Tracks Biotherapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

First Tracks Biotherapeutics OCF Yield % Related Terms

First Tracks Biotherapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics OCF Yield % Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
OCF Yield %
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
OCF Yield % 0.00 0.00

HAM:B43 vs ALT, RGNX, MDXG: OCF Yield % Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

First Tracks Biotherapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's OCF Yield % falls into.


HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

First Tracks Biotherapeutics's OCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-120.145 / 0
=N/A%

First Tracks Biotherapeutics's annualized OCF Yield % for the quarter that ended in Dec. 2024 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-120.145 * 1 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -9.95 mean?
First Tracks Biotherapeutics (HAM:B43) has a OCF Yield % of -9.95 as of Jul. 13, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #760 out of 1410 companies in the Biotechnology industry, placing it in the top 53.9%.
Is First Tracks Biotherapeutics' OCF Yield % too high?
First Tracks Biotherapeutics' current OCF Yield % is -9.95. Based on the distribution chart, First Tracks Biotherapeutics ranks #760 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' OCF Yield % compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #760 out of 1410 companies for OCF Yield %. This places First Tracks Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current OCF Yield % is -9.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current OCF Yield % of -9.95. The current OCF Yield % is -9.95. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current OCF Yield % is -9.95 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price